Abraxis buys manufacturing facility from Watson

This facility, which has the ability to manufacture lyophilized powders, suspension products, and aqueous and oil solutions, currently manufactures products for both Watson and other third parties, according to Abraxis. Under the terms of the agreement, Abraxis will serve as a contract manufacturer for certain injectable products currently manufactured in this facility for a specified period of time.

The facility is approximately 200,000 square feet and includes manufacturing as well as chemistry and microbiology laboratories. Abraxis expects that this facility, along with its manufacturing facility located in Melrose Park, Illinois, will manufacture the company’s products for the global market after completion of the planned separation of its proprietary product business, Abraxis Oncology and Abraxis Research, from its hospital-based product business, Abraxis Pharmaceutical Products.

Abraxis said that it will continue to work closely with state and local officials to secure the necessary support to sustain long-term growth of this facility.

Patrick Soon-Shiong, CEO and executive chairman of Abraxis, said: “The acquisition of this facility will allow us to expand our cGMP manufacturing capabilities to provide the necessary infrastructure for worldwide growth of the new Abraxis BioScience.”